Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
Authors:
- Martin N. FranssonMFMartin N. Fransson
- Henrik GréenHenrik Gréen
- Jan-Eric LittonJLJan-Eric Litton
- Lena E. FribergLFLena E. Friberg
- 1 February 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (2) , 247-255
Abstract
The formulation vehicle Cremophor EL has previously been shown to affect paclitaxel kinetics, but it is not known whether it also affects the kinetics of paclitaxel metabolites. This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter. In this study we used the population pharmacokinetic approach to explore the influence of predicted Cremophor EL concentrations on paclitaxel (Taxol) metabolites. In addition, correlations between genetic polymorphisms and enzyme activity with clearance of paclitaxel, its two primary metabolites, 6α-hydroxypaclitaxel and p-3′-hydroxypaclitaxel, and its secondary metabolite, 6α-p-3′-dihydroxypaclitaxel were investigated. Model building was based on 1156 samples from a study with 33 women undergoing paclitaxel treatment for gynecological cancer. Total concentrations of paclitaxel were fitted to a model described previously. One-compartment models characterized unbound metabolite concentrations. Total concentrations of 6α-hydroxypaclitaxel and p-3′-hydroxypaclitaxel were strongly dependent on predicted Cremophor EL concentrations, but this association was not found for 6α-p-3′-dihydroxypaclitaxel. Clearance of 6α-hydroxypaclitaxel (fraction metabolized) was significantly correlated (p < 0.05) to the ABCB1 allele G2677T/A. Individuals carrying the polymorphisms G/A (n = 3) or G/G (n = 5) showed a 30% increase, whereas individuals with polymorphism T/T (n = 8) showed a 27% decrease relative to those with the polymorphism G/T (n = 17). The correlation of G2677T/A with 6α-hydroxypaclitaxel has not been described previously but supports other findings of the ABCB1 transporter playing a part in paclitaxel metabolism.Keywords
This publication has 33 references indexed in Scilit:
- Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerThe Pharmacogenomics Journal, 2010
- Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2009
- Comparison of two types of population pharmacokinetic model structures of paclitaxelEuropean Journal of Pharmaceutical Sciences, 2008
- Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interfaceRapid Communications in Mass Spectrometry, 2006
- mdr-1Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel ChemotherapyClinical Cancer Research, 2006
- Use of Prior Information to Stabilize a Population Data AnalysisJournal of Pharmacokinetics and Pharmacodynamics, 2002
- Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity RelationshipDrug Metabolism and Disposition, 2002
- Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.Journal of Clinical Oncology, 1995
- Isolation, Structural Determination, and Biological Activity of 6.alpha.-Hydroxytaxol, the Principal Human Metabolite of TaxolJournal of Medicinal Chemistry, 1994
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989